ShockWave Medical, Inc. (SWAV) gained in the after-hours market after announcing its fourth quarter and fiscal 2021 results. SWAV values at $147.49, losing more than 3% compared to yesterday’s closing price. The stock closed at $142.86 at the end of the last trading session. The stock volume traded in the last trading session was around 463.86K shares. The current market cap of the company is around $5.21 billion.
SWAV: Key Financials
- ShockWave Medical, Inc. (SWAV) revenue in Q4 2021 was $84.2 million. It is a gain of more than 271% compared to the revenue of Q4 in 2020.
- Fiscal year revenue was $237 million, and it is an increase of more than 250% compared to the revenue in fiscal 2020.
- The company’s net income in Q4 2021 was around $12.9 million. The net loss in Q4 2020 was around $15.9 million.
- SWAV net income in fiscal 2021 was around $9.1 million. The company improved its loss from $65.7 million to $9.1 million in one year.
- In Q4 2021, SWAV’s basic net income per share was $0.37. Diluted earnings per share were $0.34 in Q4 of 2021.
- For fiscal 2021, the loss per share was $0.26.
SWAV President and CEO’s Remarks
Although faced with unexpected and unusual challenges, Shockwave Medical President and CEO Doug Godshall say his staff continues to perform effectively. In 2021, regulatory, sales, reimbursement, marketing, and operations performed well. He continued that employees and consumers have helped us improve patient outcomes for calcified vascular disease.
SWAV 2022 Outlook
During the entire year 2022, Shockwave Medical expects sales to be in the $405 million to $425 million range, an increase of 71-79 percent compared to revenues for the full year 2021.
Conclusion
The company’s stock has rallied in the after-hours due to its announcement of fiscal 2021 results. The debut of Shockwave C2 in February and the development of the US sales team and foreign distributor network drove revenue. Investors are investing in the stock due to its performance.
